EU Agency Has No New Concerns on Incretin Diabetes Drugs EU Agency Has No New Concerns on Incretin Diabetes Drugs

Current data do not confirm recent concerns over an increased risk for pancreatic adverse events with GLP-1-based type 2 diabetes drugs, says the European Medicines Agency. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news